Company news
Neuren Pharmaceuticals Limited news in 2019
Neuren Pharmaceuticals Limited's news releases, calls and decks from 2019, newest first.
2019 year-end update and 2020 outlook
December 11, 2019
Patent to 2034 granted in Europe for Neurens NNZ-2591
December 2, 2019
Phase 3 trial of trofinetide in Rett syndrome commences
October 30, 2019
FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
October 17, 2019
FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
October 15, 2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
October 11, 2019
Neuren approaching key milestones in Q4 2019
September 20, 2019
NNZ-2591 positive effects in Pitt Hopkins syndrome model
May 17, 2019
NNZ-2591 positive effects in Angelman syndrome model
May 16, 2019
Update on development plan for NNZ-2591
April 26, 2019
Neurens Rett syndrome Phase 2 trial published in Neurology
March 27, 2019
Preliminary Final Report and statutory accounts
February 27, 2019
NNZ-2591 positive effects in Phelan-McDermid syndrome model
February 17, 2019
Decks in 2019
- Investor Presentation (October 2019)
Investor deck · 36 slides · Oct 18, 2019